Last reviewed · How we verify
MOEXIPRIL
Moexipril is a marketed antihypertensive drug with a well-established presence in the hypertension treatment landscape. Its key strength lies in its mechanism of action, which effectively reduces blood pressure, positioning it as a reliable option for patients. The primary risk to moexipril's market position is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | MOEXIPRIL |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
- Hypertension
Boxed warnings
- WARNING FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue moexipril hydrochloride tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity
Common side effects
- Cough Increased
- Dizziness
- Diarrhea
- Flu Syndrome
- Fatigue
- Pharyngitis
- Flushing
- Rash
- Myalgia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions (PHASE1)
- Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions (PHASE1)
- Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients (NA)
- A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOEXIPRIL CI brief — competitive landscape report
- MOEXIPRIL updates RSS · CI watch RSS